Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
Dr. S Subramanian, practicing in VS Hospital, Dr. Anita Ramesh at HCG Hospital, and Dr. Saravanan Periasamy in VS Hospital Chennai, are some of the renowned oncologists in Chennai. If you're looking for the best cancer specialists in Chennai, consulting them would be a wise decision. If you're ex....
Study findings on a potential link between breast size and breast cancer have been mixed. Some studies have found having a larger breast size increases risk, while others have found no link between breast size and risk but few studies have suggested that breast size increases risk among thin women,....
Cancer attacks your body due to a random mutation of cells that gets out of control and spreads. The majority of breast cancers are hereditary, or blind unlucky chance. Fat is not directly linked with the enhanced cancer risk factor but it affects the estrogen hormone balance in your body which play....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
लिहिलेले:Dr. Nitika Sharma - BDS
पुनरावलोकन:Dr. Rakesh Kumar - MBBS, MS
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.